[A Case of Cholangiocellular Carcinoma in Lynch Syndrome Treated by an Immune Checkpoint Inhibitor].
Journal
Gan to kagaku ryoho. Cancer & chemotherapy
ISSN: 0385-0684
Titre abrégé: Gan To Kagaku Ryoho
Pays: Japan
ID NLM: 7810034
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
entrez:
19
1
2022
pubmed:
20
1
2022
medline:
22
1
2022
Statut:
ppublish
Résumé
We report a case of cholangiocellular carcinoma(CCC)with high-frequency microsatellite instability(MSI-H)in Lynch syndrome that was managed using a multimodal treatment approach including an immune checkpoint inhibitor. The patient was a 74-year-old man who presented with fever as the chief complaint. He had a history of Vater's papilla cancer and colorectal cancer in Lynch syndrome. A diagnosis of CCC in the left lobe of the liver was made, and left hepatectomy and left caudate lobectomy were performed. From about 2 years and 5 months after the operation, the patient developed several episodes of cholangitis, and recurrence of CCC was diagnosed based on the results of biliary cytology. Gemcitabine and cisplatin therapy was started, but exacerbation of bile duct stenosis associated with cancer progression was observed, and pembrolizumab, an immune checkpoint inhibitor, was started as the solid cancer had an MSI-H status. The tumor markers then improved and the cholangitis subsided. We experienced a case of recurrence of CCC with MSI-H in Lynch syndrome managed by multimodal treatment including an immune checkpoint inhibitor.
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Case Reports
Journal Article
Langues
jpn
Sous-ensembles de citation
IM